• Adipose-Neural Signaling in Cardiac Arrhythmia

  2026-08-13

  Fan et al. developed a stem-cell-based coculture model showing how epicardial adipose tissue can communicate with sympathetic neurons and cardiomyocytes through a leptin–NPY/Y1R pathway. The study connects adipocyte-derived leptin, neuronal NPY release, NCX activity, and CaMKII signaling to arrhythmic phenotypes, while patient data support clinical relevance in atrial fibrillation.

• Berberrubine and NAFLD: Metabolic and Microbiota Effects

  2026-08-13

  This study identifies berberrubine, a major metabolite of berberine, as an active contributor to protection against non-alcoholic fatty liver disease. Using high-fat diet mice, oleic acid-treated HepG2 cells, metabolic protein profiling, and 16S rRNA sequencing, the authors connect improved hepatic steatosis and glucose handling with altered lipid pathways and gut microbial composition.

• Prednisolone and the Next Era of Glucocorticoid Research

  2026-08-12

  Prednisolone remains a powerful benchmark for glucocorticoid receptor biology, inflammation modulation, and immunology research. Emerging ERAD-engaging chimeras now add a complementary strategy for controlling protein abundance, creating a more rigorous framework for translational comparison without conflating receptor activation with targeted degradation.

• BIBP 3226: Translating NPY/NPFF Mechanisms

  2026-08-12

  A translational strategy for using BIBP 3226 trifluoroacetate to dissect NPY Y1 and NPFF signaling, validate the adipose-neural axis, and strengthen cardiovascular, anxiety, and analgesia research workflows.

• Omeprazole (A2845): Protocol and QC Guide

  2026-08-11

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, acid-formation assays, and antiulcer activity studies. This guide covers preparation, assay controls, storage, and failure prevention; the material is for scientific research only and not for diagnostic, clinical, or therapeutic use.

• Aprotinin: Protease Control in Nascent RNA Assays

  2026-08-11

  Aprotinin, or bovine pancreatic trypsin inhibitor, is best understood not only as a fibrinolysis-modulating reagent but also as a variable in preanalytical assay design. This article connects its serine-protease pharmacology with the rRNA-depleted GRO-seq workflow and defines where that cross-domain application is useful, unvalidated, or potentially misleading.

• IL-17A and Neonatal Risk in GBS-Colonized Pregnancies

  2026-08-10

  A prospective mother–newborn study in Morocco found that reduced maternal IL-17A, alongside lower IL-1β and IL-4 responses, was associated with invasive GBS disease in newborns. The work positions circulating IL-17A as a candidate risk-stratification biomarker and shows how ex vivo TLR1/2 and TLR4 stimulation can complement clinical cytokine profiling.

• MTT Assays for Drug-Resistant Cancer Translation

  2026-08-09

  A mechanism-first guide to using MTT as a metabolic readout in drug-resistant cancer research, with translational strategy for nanoparticle evaluation, assay design, interpretation, and product selection.

• How Cholesterol Hinders LNP Intracellular Trafficking

  2026-08-08

  The reference study introduces a sensitive streptavidin–biotin-DNA tracking and high-throughput imaging strategy to resolve how lipid nanoparticle composition affects intracellular movement. Its central finding is that excess cholesterol promotes aggregation of LNP-containing peripheral early endosomes, limiting endolysosomal progression and reducing nucleic-acid delivery efficiency.

• Reversine Aurora Kinase Inhibitor Workflows

  2026-08-07

  Reversine connects mechanistic mitosis research with practical cancer-cell assays and emerging single-object gastruloid screening. This guide explains dose design, apoptosis and cell-cycle readouts, microraft-compatible workflows, and troubleshooting for reproducible Aurora kinase studies.

• Synergistic CDK4/6 and BET Inhibition Suppresses PDAC via Wn

  2026-08-07

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition yields synergistic suppression of pancreatic ductal adenocarcinoma growth and epithelial-to-mesenchymal transition by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight informs targeted combination strategies for overcoming tumor progression and metastatic risk in pancreatic cancer.

• Adipose-Neural Axis and Cardiac Arrhythmias: Leptin–NPY/Y1R

  2026-08-06

  Fan et al. (2024) present a stem cell-based coculture model revealing the critical role of the adipose-neural axis, specifically the leptin–NPY/Y1 receptor pathway, in epicardial adipose tissue (EAT)-related cardiac arrhythmias. Their findings highlight new mechanistic insights and therapeutic targets for atrial fibrillation and related conditions.

• Syringin Natural Product: Mechanistic Leverage in RCC Resear

  2026-08-06

  This thought-leadership article explores the emerging role of Syringin, a bioactive natural product, in overcoming sunitinib resistance in renal cell carcinoma (RCC) via EGFR/PI3K/Akt pathway modulation. Integrating mechanistic insights, experimental guidance, and strategic outlook, it empowers translational researchers to navigate and accelerate bioactive compound innovation.

• NADPH Oxidase-ROS Drive Arterial Contraction via L-type Ca2+

  2026-08-05

  A recent study clarifies how NADPH oxidase-derived reactive oxygen species (ROS) promote arterial contraction in early postnatal rats, revealing a direct role for L-type voltage-gated Ca2+ channels (LTCC) rather than classical kinase pathways. These insights refine our understanding of vascular developmental biology and the specificity of ROS signaling.

• PCI-32765 (Ibrutinib): Applied BTK Inhibition for B-Cell Stu

  2026-08-05

  PCI-32765 (Ibrutinib) offers robust, irreversible BTK inhibition, empowering researchers to precisely dissect B-cell receptor signaling and model disease-relevant phenotypes. This guide delivers actionable workflow enhancements, troubleshooting strategies, and evidence-backed assay parameters for chronic lymphocytic leukemia and autoimmune disease research.

8513 records 9/568 page Previous Next First page 上5页 678910 下5页 Last page